Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management
Michael Pazianas, Paul D. Miller
Abstract
D, and the development of renal osteodystrophy, including secondary hyperparathyroidism (HPT) and its catabolic effects on the skeleton. Even in more advanced stages of CKD that have not progressed to tertiary HPT, could be beneficial. Therapeutic effects could be achieved in vascular calcification as well. Limited experimental/clinical data support the effectiveness of PTH in CKD-MBD. Its safety, has been established only when it is used for the treatment of osteoporosis, including patients with CKD. The proposed intermittent PTH administration is biologically plausible but its effectiveness and safety has to be critically assessed in long term prospective studies in patients with CKD-MBD.
Topics & Concepts
MedicineRenal osteodystrophySecondary hyperparathyroidismParathyroid hormoneKidney diseaseFibroblast growth factor 23Chronic kidney disease-mineral and bone disorderInternal medicineHyperphosphatemiaEndocrinologyHyperparathyroidismVitamin D and neurologyOsteoporosisBone remodelingCalciumParathyroid Disorders and TreatmentsGenetic Syndromes and ImprintingBone health and treatments